Myasthenia gravis (MG): Epidemiological data and prognostic factors

Renato Mantegazza, Fulvio Baggi, Carlo Antozzi, Paolo Confalonieri, Lucia Morandi, Pia Bernasconi, Francesca Andreetta, Ornella Simoncini, Angela Campanella, Ettore Beghi, Ferdinando Cornelio

Research output: Contribution to journalArticle

Abstract

Data from 756 myasthenic patients were analyzed for diagnostic criteria, clinical aspects, and therapeutic approaches. The patients were followed up at our institution from 1981 to 2001. Clinical evaluation was performed according to the myasthenia gravis score adopted at our clinic. Clinical features of each patient (comprising demographic, clinical, neurophysiological, immunological, radiological, and surgical data, as well as serial myasthenia gravis scores) were filed in a relational database containing more than 7000 records. Clinical efficacy and variables influencing outcome were assessed by life-table methods and Cox proportional hazards regression analysis. Complete stable remission, as defined by the Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, was the end point for good prognosis. Four hundred and ninety-nine patients (66%) were female and 257 (34%) were male. Mean follow-up was 55.1 ± 48.1 months. Onset of symptoms peaked in the third decade in females, whereas the male distribution was bimodal with peaks in the third and sixth decades. Modality of myasthenia gravis presentation was as follows: ocular, 39.3%; generalized, 28.5%; bulbar, 31.3%; and respiratory, 0.8%. Thymectomy was carried out on 63.7% of our patients by different approaches: (1) transcervical; (2) transsternal; (3) video-thoracoscopic mini-invasive surgery. The last approach has been preferentially used in more recent years and accounted for 62.4% of the thymectomized myasthenia gravis population. Univariate analysis and Kaplan-Meier analysis showed that variables such as sex (female), age at onset (below 40 years), thymectomy, and histological diagnosis of thymic hyperplasia were significantly associated with complete stable remission, whereas on multivariate analysis only age at onset below 40 years and thymectomy were confirmed.

Original languageEnglish
Pages (from-to)413-423
Number of pages11
JournalAnnals of the New York Academy of Sciences
Volume998
DOIs
Publication statusPublished - 2003

Fingerprint

Myasthenia Gravis
Regression analysis
Surgery
Hazards
Thymectomy
Age of Onset
Thymus Hyperplasia
Life Tables
Muscle Weakness
Kaplan-Meier Estimate
Advisory Committees
Multivariate Analysis
Regression Analysis
Demography
Databases
Population
Onset
Remission

Keywords

  • Database
  • Diagnosis
  • Myasthenia gravis (MG)
  • Prognostic factor

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Myasthenia gravis (MG) : Epidemiological data and prognostic factors. / Mantegazza, Renato; Baggi, Fulvio; Antozzi, Carlo; Confalonieri, Paolo; Morandi, Lucia; Bernasconi, Pia; Andreetta, Francesca; Simoncini, Ornella; Campanella, Angela; Beghi, Ettore; Cornelio, Ferdinando.

In: Annals of the New York Academy of Sciences, Vol. 998, 2003, p. 413-423.

Research output: Contribution to journalArticle

@article{93bbb31d3a7f4cbcad462b2b7239373e,
title = "Myasthenia gravis (MG): Epidemiological data and prognostic factors",
abstract = "Data from 756 myasthenic patients were analyzed for diagnostic criteria, clinical aspects, and therapeutic approaches. The patients were followed up at our institution from 1981 to 2001. Clinical evaluation was performed according to the myasthenia gravis score adopted at our clinic. Clinical features of each patient (comprising demographic, clinical, neurophysiological, immunological, radiological, and surgical data, as well as serial myasthenia gravis scores) were filed in a relational database containing more than 7000 records. Clinical efficacy and variables influencing outcome were assessed by life-table methods and Cox proportional hazards regression analysis. Complete stable remission, as defined by the Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, was the end point for good prognosis. Four hundred and ninety-nine patients (66{\%}) were female and 257 (34{\%}) were male. Mean follow-up was 55.1 ± 48.1 months. Onset of symptoms peaked in the third decade in females, whereas the male distribution was bimodal with peaks in the third and sixth decades. Modality of myasthenia gravis presentation was as follows: ocular, 39.3{\%}; generalized, 28.5{\%}; bulbar, 31.3{\%}; and respiratory, 0.8{\%}. Thymectomy was carried out on 63.7{\%} of our patients by different approaches: (1) transcervical; (2) transsternal; (3) video-thoracoscopic mini-invasive surgery. The last approach has been preferentially used in more recent years and accounted for 62.4{\%} of the thymectomized myasthenia gravis population. Univariate analysis and Kaplan-Meier analysis showed that variables such as sex (female), age at onset (below 40 years), thymectomy, and histological diagnosis of thymic hyperplasia were significantly associated with complete stable remission, whereas on multivariate analysis only age at onset below 40 years and thymectomy were confirmed.",
keywords = "Database, Diagnosis, Myasthenia gravis (MG), Prognostic factor",
author = "Renato Mantegazza and Fulvio Baggi and Carlo Antozzi and Paolo Confalonieri and Lucia Morandi and Pia Bernasconi and Francesca Andreetta and Ornella Simoncini and Angela Campanella and Ettore Beghi and Ferdinando Cornelio",
year = "2003",
doi = "10.1196/annals.1254.054",
language = "English",
volume = "998",
pages = "413--423",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Myasthenia gravis (MG)

T2 - Epidemiological data and prognostic factors

AU - Mantegazza, Renato

AU - Baggi, Fulvio

AU - Antozzi, Carlo

AU - Confalonieri, Paolo

AU - Morandi, Lucia

AU - Bernasconi, Pia

AU - Andreetta, Francesca

AU - Simoncini, Ornella

AU - Campanella, Angela

AU - Beghi, Ettore

AU - Cornelio, Ferdinando

PY - 2003

Y1 - 2003

N2 - Data from 756 myasthenic patients were analyzed for diagnostic criteria, clinical aspects, and therapeutic approaches. The patients were followed up at our institution from 1981 to 2001. Clinical evaluation was performed according to the myasthenia gravis score adopted at our clinic. Clinical features of each patient (comprising demographic, clinical, neurophysiological, immunological, radiological, and surgical data, as well as serial myasthenia gravis scores) were filed in a relational database containing more than 7000 records. Clinical efficacy and variables influencing outcome were assessed by life-table methods and Cox proportional hazards regression analysis. Complete stable remission, as defined by the Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, was the end point for good prognosis. Four hundred and ninety-nine patients (66%) were female and 257 (34%) were male. Mean follow-up was 55.1 ± 48.1 months. Onset of symptoms peaked in the third decade in females, whereas the male distribution was bimodal with peaks in the third and sixth decades. Modality of myasthenia gravis presentation was as follows: ocular, 39.3%; generalized, 28.5%; bulbar, 31.3%; and respiratory, 0.8%. Thymectomy was carried out on 63.7% of our patients by different approaches: (1) transcervical; (2) transsternal; (3) video-thoracoscopic mini-invasive surgery. The last approach has been preferentially used in more recent years and accounted for 62.4% of the thymectomized myasthenia gravis population. Univariate analysis and Kaplan-Meier analysis showed that variables such as sex (female), age at onset (below 40 years), thymectomy, and histological diagnosis of thymic hyperplasia were significantly associated with complete stable remission, whereas on multivariate analysis only age at onset below 40 years and thymectomy were confirmed.

AB - Data from 756 myasthenic patients were analyzed for diagnostic criteria, clinical aspects, and therapeutic approaches. The patients were followed up at our institution from 1981 to 2001. Clinical evaluation was performed according to the myasthenia gravis score adopted at our clinic. Clinical features of each patient (comprising demographic, clinical, neurophysiological, immunological, radiological, and surgical data, as well as serial myasthenia gravis scores) were filed in a relational database containing more than 7000 records. Clinical efficacy and variables influencing outcome were assessed by life-table methods and Cox proportional hazards regression analysis. Complete stable remission, as defined by the Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, was the end point for good prognosis. Four hundred and ninety-nine patients (66%) were female and 257 (34%) were male. Mean follow-up was 55.1 ± 48.1 months. Onset of symptoms peaked in the third decade in females, whereas the male distribution was bimodal with peaks in the third and sixth decades. Modality of myasthenia gravis presentation was as follows: ocular, 39.3%; generalized, 28.5%; bulbar, 31.3%; and respiratory, 0.8%. Thymectomy was carried out on 63.7% of our patients by different approaches: (1) transcervical; (2) transsternal; (3) video-thoracoscopic mini-invasive surgery. The last approach has been preferentially used in more recent years and accounted for 62.4% of the thymectomized myasthenia gravis population. Univariate analysis and Kaplan-Meier analysis showed that variables such as sex (female), age at onset (below 40 years), thymectomy, and histological diagnosis of thymic hyperplasia were significantly associated with complete stable remission, whereas on multivariate analysis only age at onset below 40 years and thymectomy were confirmed.

KW - Database

KW - Diagnosis

KW - Myasthenia gravis (MG)

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=0141504280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141504280&partnerID=8YFLogxK

U2 - 10.1196/annals.1254.054

DO - 10.1196/annals.1254.054

M3 - Article

C2 - 14592909

AN - SCOPUS:0141504280

VL - 998

SP - 413

EP - 423

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -